The San Francisco Business Times (Free subscription) | 01/12/2008
A $45 billion syndicated loan for Roche’s buyout of South San Francisco’s Genentech Inc. is becoming tougher to get, and the Swiss drugmaker is seeking alternatives, Reuters reported. (DNA)
Global Financial News (Free subscription) | 24/11/2008
Filed under: Major movement , Good news , Genentech Inc (DNA) , Options , Technical Analysis Genentech (NYSE: DNA - option chain ) shares have moved higher today after the company and its partner Roche announced its breast-cancer drug Avastin improved the survival time for patients in a late-stage study . The results bring DNA one step closer to full regulatory approval from the FDA....
InformedTrades (Free subscription) | 24/11/2008
TEL AVIV (MarketWatch) -- Genentech Inc., the South San Francisco biotech major, said that in a Phase III study, Avastin -- combined with taxane,...
Market Watch (Free subscription) | 24/11/2008
TEL AVIV (MarketWatch) -- Genentech Inc., the South San Francisco biotech major, said that in a Phase III study, Avastin -- combined with taxane, anthracycline-based or capecitabine chemotherapies for first-line treatment of metastatic HER2-negative breast cancer -- "met its primary endpoint of increasing the time patients lived without their disease advancing, compared with the chemotherapies...
BloggingStocks (Free subscription) | 24/11/2008
Filed under: Major movement , Good news , Genentech Inc (DNA) , Options , Technical Analysis Genentech (NYSE: DNA - option chain ) shares have moved higher today after the company and its partner Roche announced its breast-cancer drug Avastin improved the survival time for patients in a late-stage study . The results bring DNA one step closer to full regulatory approval from the FDA....
Law Blog - WSJ.com (Free subscription) | 25/11/2008
Genentech said a study found Avastin delayed progression of breast cancer when combined with common chemotherapies.
Reuters (Free subscription) | 09/11/2008
ZURICH (Reuters) - Roche Holding AG is sticking by its $43.7 billion offer to buy out the rest of Genentech Inc it does not already own, its pharmaceuticals chief said in an interview published on Sunday.
The Sacramento Business Journal (Free subscription) | 03/11/2008
Genentech Inc. is seeking accelerated FDA approval of Avastin — the South San Francisco company’s No. 1 drug — to fight the most aggressive form of brain cancer. (DNA)
The East Bay Business Times (Free subscription) | 03/11/2008
Genentech Inc. is seeking accelerated FDA approval of Avastin — the South San Francisco company’s No. 1 drug — to fight the most aggressive form of brain cancer. (DNA)
The East Bay Business Times (Free subscription) | 31/10/2008
Genentech Inc. will be paid $31.5 million upfront in a deal with Biogen Idec. (BIIB) (DNA)
Reuters (Free subscription) | 21/10/2008
ZURICH (Reuters) - Swiss drugmaker Roche Holding AG confirmed its commitment to a $43.7 billion bid for Genentech Inc as it reported a 2 percent fall in nine-month sales to 33.3 billion Swiss francs ($29.26 billion).
Boston Globe (Free subscription) | 21/10/2008
Swiss drugmaker Roche Holding AG confirmed its commitment to a $43.7 billion bid for Genentech Inc as it reported a 2 percent fall in nine-month sales to 33.3 billion Swiss francs ($29.26 billion).
Reuters UK (Free subscription) | 22/10/2008
By Maggie Fox, Health and Science EditorWASHINGTON (Reuters) - Researchers have discovered stem cells in the prostates of mice and grown complete prostates from them, a big step toward regenerating organs from a patient's own cells.The team at California-based Genentech Inc said human beings have similar stem cells in their prostates, although they have so far not grown human prostate glands...
